Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action

Core Viewpoint - Novo Nordisk is facing challenges in Wegovy sales due to the growth of the U.S. compounded drug industry, prompting the company to consider legal action against violators of its intellectual property [2][4]. Group 1: Company Actions and Responses - The FDA has declared the shortage of Wegovy over, allowing compounding pharmacies until May 22 to stop selling copies of the drug [3]. - CEO Lars Fruergaard Jørgensen indicated that the rise in compounding is negatively affecting Wegovy prescriptions in 2025 [4]. - Novo Nordisk is taking legal actions against compounding pharmacies, asserting that they are infringing on its intellectual property and harming its business [4]. Group 2: Industry Context and Competition - The Outsourcing Facilities Association (OFA) is involved in a legal dispute with Novo Nordisk, arguing against the FDA's decision to end the drug shortage, claiming it could deprive patients of essential treatments [5]. - Demand for compounded obesity drugs has surged due to high costs and limited availability of branded treatments, although these compounded products are not FDA approved [5]. - Concerns have been raised about the safety and quality of compounded alternatives, with reports of impurities and banned substances found in some products [6]. Group 3: Financial Performance and Market Outlook - Novo Nordisk reported better-than-expected net profit in the fourth quarter, driven by high demand for Wegovy, but anticipates a slight slowdown in sales for 2025 [8]. - Following the Annual General Meeting, Novo Nordisk shares fell by 3.8%, reflecting investor concerns amid increased competition and disappointing trial results for obesity drugs [9].